Cargando…

Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors

Adaptive drug resistance is a major obstacle to successful treatment of colorectal cancers. Physiologic tumor models of drug resistance are crucial to understand mechanisms of treatment failure and improve therapy by developing new therapeutics and treatment strategies. Using our aqueous two-phase s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahi Thakuri, Pradip, Luker, Gary D., Tavana, Hossein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2018
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299152/ https://www.ncbi.nlm.nih.gov/pubmed/30550927 http://dx.doi.org/10.1016/j.tranon.2018.11.009

Ejemplares similares

Three-dimensional tumor model mimics stromal – breast cancer cells signaling
por: Ham, Stephanie Lemmo, et al.
Publicado: (2017)

Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells
por: Lamichhane, Astha, et al.
Publicado: (2023)

Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling
por: Shahi Thakuri, Pradip, et al.
Publicado: (2020)

Cancer-associated fibroblasts: challenges and opportunities
por: Tavana, Hossein, et al.
Publicado: (2023)

Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors
por: Martinez, Ramon, et al.
Publicado: (2022)

High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroids
por: Folkesson, Evelina, et al.
Publicado: (2020)

Imaging Sensitivity of Quiescent Cancer Cells to Metabolic Perturbations in Bone Marrow Spheroids
por: Cavnar, Stephen P., et al.
Publicado: (2016)

Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells
por: Tsubaki, Masanobu, et al.
Publicado: (2019)

Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
por: Bhattacharya, Bhaskar, et al.
Publicado: (2016)

Author Correction: High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroids
por: Folkesson, Evelina, et al.
Publicado: (2020)

Optimal Control Model of Tumor Treatment with Oncolytic Virus and MEK Inhibitor
por: Su, Yongmei, et al.
Publicado: (2016)

MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer
por: Zhan, Tianzuo, et al.
Publicado: (2019)

Oscillatory ERK Signaling and Morphology Determine Heterogeneity of Breast Cancer Cell Chemotaxis via MEK-ERK and p38-MAPK Signaling Pathways
por: Ho, Kenneth K. Y., et al.
Publicado: (2023)

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
por: Küsters-Vandevelde, Heidi VN, et al.
Publicado: (2014)

Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo
por: Fan, Fan, et al.
Publicado: (2023)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway
por: Ogishima, Juri, et al.
Publicado: (2018)

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma
por: Mergener, Svenja, et al.
Publicado: (2021)

Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
por: Koroknai, Viktoria, et al.
Publicado: (2020)

Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with resistance to chemotherapy treatment
por: Däster, Silvio, et al.
Publicado: (2016)

Role of circulating tumor cell spheroids in drug resistance
por: Hamilton, Gerhard, et al.
Publicado: (2019)

MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells
por: Jing, Changwen, et al.
Publicado: (2019)

The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis
por: Kobelt, Dennis, et al.
Publicado: (2021)

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor
por: Dumble, Melissa, et al.
Publicado: (2014)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
por: Davis, Thomas B., et al.
Publicado: (2019)

PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors
por: Smith, Amanda M., et al.
Publicado: (2019)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Macrophage induces anti-cancer drug resistance in canine mammary gland tumor spheroid
por: Lim, Ga-Hyun, et al.
Publicado: (2023)

Colorectal cancer-associated anaerobic bacteria proliferate in tumor spheroids and alter the microenvironment
por: Kasper, Stephen H., et al.
Publicado: (2020)

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
por: Chen, Wenjing, et al.
Publicado: (2023)

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2018)

Cellular and Molecular Mechanisms of MEK1 Inhibitor–Induced Cardiotoxicity
por: Beck, Tyler C., et al.
Publicado: (2022)

MEK inhibitors for the treatment of non-small cell lung cancer
por: Han, Jing, et al.
Publicado: (2021)

P1097: MEK-INHIBITORS IN TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS
por: Burtsev, E., et al.
Publicado: (2022)

Hyperthermia Induced by Gold Nanoparticles and Visible Light Photothermy Combined with Chemotherapy to Tackle Doxorubicin Sensitive and Resistant Colorectal Tumor 3D Spheroids
por: Roma-Rodrigues, Catarina, et al.
Publicado: (2020)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_u98sh16lbtsnkb557huhrb1jh1